Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to Voyager Therapeutics Third Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that the call is being recorded at the company’s request. A replay of today’s call will be available on the investor section of the company’s website approximately two hours after the conclusion of the call.

to Officer. call like Pfreundschuh, to now Financial Chief would turn over the Peter I

Peter Pfreundschuh

for and majority morning. press of brief you plan Accordingly, press quarter are Thank we good the on key to release of financial third available reserve your to in and this highlights results be quarter are very Q&A. from morning. today’s website. going summary The our release time efficient XX-Q We and the We issued call. our a provide

In over a the call I will moment, turn to Al.

that want do this, statement differ to remind I and this risks statements. are Before those may during from expectations, and materially uncertainties call, future representatives I prospects. by cause forward-looking to make actual uncertain these everyone statements forward-looking forward-looking to inherently may results that indicated All plans Voyager subject regarding and

and XX-K quarterly review uncertainties the number to Form the Form on facing encouraged on recent the SEC SEC company’s by filings available most XX-Q company including website. on subsequent the and the company’s as filings the are understand morning. described in All SEC, as this filed material are report risks company’s filed updated report a You with annual of

to pleasure turn my is Sandrock. it Now Executive over Voyager’s the to Officer, call Chief Al Dr.

Alfred Sandrock

and is therapy you Pete, gene company everyone. Voyager Thank a breaking summarizing thesis. barriers and I morning, in biotechnology would good by dedicated and investment like to Voyager’s start through neurology. to

the getting challenges. molecules therapy narrow windows issues. therapeutic The blood-brain-barrier. limited Neurology safety potential has by difficulty limited larger of has and been by for disciplines the constrained by Gene both across been associated delivery is

we deep to constraints, discovery, expertise address in we shareholders. create for Voyager, cutting which are ultimately pharmacology capabilities At will value and and significant neuro patients these capsid leveraging believe edge

at value of pillars three Voyager. created have We

partnerships. pipeline significant TRACER that Pfizer for our future Novartis discovery capsids partners with and fuel generating potential platform including of breakthrough is First, own to and our capsids Neurocrine, both

is million TRACER system. our only of organs. in in-vivo XX At our AAVX allowed the proprietary of displayed capsids those to capsids transduction select This increased variants and screening core has than driven the target team AAVX more that expression evaluate and

preclinical We central demonstrated trans-gene have conventional brain XXX compared have and than more expression in started targeting AAVX higher we capsids. fold in nervous studies, system, the the by to

We have also our across increases species, may non-human confidence be which multiple demonstrated able that we blood-brain-barrier these translate mice including penetration to to primates, humans. properties and

[XXX%] high by month, therapeutic a novel potentially of therapies. last in At we that demonstrated gene administered CNS intravenously a range capsid (Ph) ESGCT of on presented the of levels improving of doses expression when window data the used capsids, gene conventional

in data receptor and Further, families novel we further In receptor this for and we translate cell discovery of expression our humans. function of characterizing a we are this confirmed that near-term, seeing one the clinical capsids trial. our increases surface results confidence analogous preclinical into the human presented binding the may

generated platform. could In enable our engineering this further by capsids receptor enhance the the longer-term, TRACER to reverse

protein this such constitute receptor new across have whether enable platform a delivery CNS we which be modalities to explore therapeutic addition, experiments to leverage could for In may successful and development. begun blood-brain-barrier, the we if as to drug of able the oligonucleotide

XXXX. exercise companies. and discussions $XX revenue of triggered September attracted derived multiple the Pfizer in are Pfizer’s QX to novel additional Novartis, from and in including million their in The and with have deferred decision option ongoing capsid capsids TRACER interest of pharmaceutical revenue partners, $XX multiple million

is want three validated our of value and to transformative human human CNS our of by targets advancing pipeline. review pillar is call our directed programs biology. genetics But just against I progress each out are minute. a will second the lead in I Our pipeline

achieve efficiently to biomarkers of quickly and of proof availability the exploit they a to biology. Moreover, enable path

foundation we we in next our filings XXXX the call, laying year, first half said the this candidates of IND and year into XXXX. to As these identify for expect later QX in and

We create sclerosis for burdens also disease, and and or targeting Alzheimer’s disease amyotrophic caregivers, lateral life-threatening note, significant Parkinson’s serious patients diseases ALS. are that we

our Our sheet, non-dilutive track third pillar enabled revenue. of generating value sound our partnership of is record balance by

reported As of September equivalents of and XX, XXXX, marketable securities we cash cash, million. $XXX

received expenses expenditure to sheet of the its are into balance Our licensing costs be XXXX. requirements with Voyager’s as $XX Pfizer’s the triggered sufficient cash QX XXXX. under to operating expected payment along in Neurocrine to amounts million expected and position development capital for collaboration be meet exercise agreement a reimbursement planned

the Novartis the enhance third-parties. the further. date in to no The obligations debt prior option QX Additionally, to exercise has company’s operating runway would expiration option potential by XXXX company

want we don’t tests that for work capsids. make on not tests our that internal else here, one around point which may I target, anybody licenses interest, select is our their capsids and with are same is this Once select possible select that that our it structured to some may also gene, the more entirely gene partners the multiple programs. own we partners of but of

structure twofold. of this benefits are The

capsids, First, to to optionality deals partnerships. continue have not because are pursue these exclusive we to the the

Second, some clinical we capsid partners of in our of our own initial they that capsids. validation programs, do may utilize also choose provide our

advance pipeline gene antibodies silencing our for gene humanized Alzheimer’s into a dig Voyager disease. and the for prioritized for continues anti-tau replacement bit three SODX disease, programs, Parkinson’s as to want to AOS I now. deeper GBAX

Phase three funding Neurocrine we programs, with to have which remind is collaboration gene to X. free a want these therapy you ongoing I ataxia, develop that a for Friedreich’s to currently addition through In Neurocrine

has Voyager and and global to grant full cost with royalties. split At Voyager or to in in XX/XX rights and from option Neurocrine profit a asset exchange at XX% that the the U.S. coming co-commercialize commercial milestones to co-develop point, an

developed pathology a has as research vein tau across Alzheimer’s IV an that tau in disease. Our program well-known certain passive regions is delivered antibody shown being propagates immunotherapy, in pattern

proof with this monitored can of imaging, and PET biology. use to plan early tau be to of The establish we pathology spread biomarker

antibody that hypothesis block may of an extracellular neuron-to-neuron is targeting at tau tau plausible spread several the therapeutic sites. Our

in Our C it that models other preclinical N in been our antibody clinical targets significantly pathological from terminal has shown and demonstrated that the antibody efficacy reduce rather not region, terminal to than of the travel. is the differentiated antibodies spread have

to with on humanize murine antibodies. track are our We work the

now genetic to XX-fold. of Moving to approximately the the mutation GBAX Parkinson’s risk common have factor, patients up a of in most increasing disease Parkinson’s disease disease XX% GBAX, risk

measured GBAX in of carriers Parkinson’s GBAX believe the encodes mutation. substrates GBAX lysosomal have abnormally mutations of enzyme, GCase benefits. of be in GCase function or CFS, as to we elevated therapeutic patients GCase, loss the can and due can are restoration GCase in that levels with will glucocerebrosidase

tropic These penetrant, development studies biomarkers replacement novel NHB approach combines select derived capsids. derisking path lead a TRACER to provide potential a gene a our candidate underway. early CNS GBAX with to clinical are BBB our

rapidly typically in three SODXALS. leads approximately ALS to progressing with We ALS after a benefit therapeutic the patients expression can neurodegenerative death now provide CNS, silencing SODX is disease believe diagnosis. SODX years by the we gene to that that And of mutations.

approach biomarker an CSF small is IONIS, a Proof-of-concept in has which demonstrated and and SODX review drug for measurable by FDA. study. under clinical sponsored as can Biogen in investigational this for a currently serve by efficient is by early [Indiscernible], proof-of-biology been

of Serum a measured or efficacy. chain also will be neurofilament to whether determine not light signal there is

novel our a Our siRNA studies CNS-tropic blood-brain-barrier constructs select NHP candidates capsids. to TRACER are penetrance, with a lead underway. derived potent approach combines

We lead continue candidates development three QX XXXX to HX for between and expect to programs all identify XXXX.

I novel want These expected partnerships IND we capsids. support lead using also in XXXX and be event filings generated to enabling TRACER with XXXX. will this on that, several IND candidates and slide studies to note have

mentioned partners I may any As clinical earlier progress even by above, our provide validation.

during believe the subsequent is third quarter to XXXX. gaining period. strong demonstrated we close towards as XXXX with has summary, our and And the Voyager and ability momentum In we validation look out the execute company

to continue In as as our addition of executive our Board Directors advancing our well to build out pipeline team. we

appointed Dr. Mackey We our to Board. Kitty

We Peter to President as CFO Scientific Corporate also Tristan we Morrison promoted Affairs. of And and Todd added Dr. Senior as Officer. Carter Chief Pfreundschuh Vice

posters platform exercise on option. data and website We further Pfizer’s we encouraging you our to the Conferences. And from seen AAIC our its if haven’t Those saw validation of are also pre-clinical TRACER them. decision presented ESGCT at

work lead keep this year of barriers of look neurology. the Looking We to first constraining gene and we the fields our as the towards you candidates to the for will identifying we our next forward, of end break between and through continue and pre-prioritized forward therapy we advance half INDs. programs pipeline year, updated

we generated have share will conferences. scientific at continue We exciting the data to

year. initial the Novartis of March decision have next also option by coming up We exercise

and scientists to working professionals. excited a the of I acknowledge and seven-months with team. now this Voyager company about so for on have CEO be everyone to I incredibly take such to talented I’m want been moment other

With are have. that, you to happy questions we may any take

our Chief for Carter, CFO Pfreundschuh, Dr. and Scientific Q&A Joining me today are Todd Officer. Peter Operator. our

Operator

comes Instructions] question ahead. go Allen Our with Thank first from Baird. you. [Operator Jack Please

Jack Allen

you have library of to taking as the can about questions, if to thinking assets? different of for you throughout well. any I color as selection, capsids any or the the capsid team strategy guess much Love the first of hear quarter that. have it development on select Thank the question moving that candidates capsid these an to was to to and so your be are kind overlapping it new wondering progress and goal roles look for you for and thoughts you you around congratulations I how provide development would Todd future relates within candidates around the would was you Pete captive to the look as forward. my selection diversify

Alfred Sandrock

said, what where the is look the our in to This and capsid for and Al, start targeting But are jump Jack. sure scientists disease, and issues. on regions programs, et will the depends which for brain, ideal Thanks, that have are cetera, this of profiles the each in. cells to Paul transduced, be also will I need characteristics want we these I’m

And select capsid. will best we so the

manufacturing be may that - that Todd. capsid But the diseases, the there our patients, most best think to same in for Now example. is we optimal obviously multiple for use approach patients advantages, for can the so I use very want treat we the certainly way. it are capsid the we if

Todd Carter

Yes.

I it think you well. captured quite

Alfred Sandrock

Todd. Thanks,

Jack Allen

just future for Great. on if follow-up then the one appetite could ask partnerships. I And

have potential bit. been are the another quite to to and as made on think and You about ongoing remark how would investors going as future for seem conversations, any going it hear a should thoughts conversations to additional that love updates the I partnerships? then call how near-term to you those on conversations have relates

Alfred Sandrock

mean, I having ongoing business. to and are multiple open Jack. Yes, conversations are we parties, Well, we with

capsids, partners gene barriers breaking We are certainly open we that sees mean, because to too else on our everybody I are for look therapy.

anything to And we to our programs, open on partnering programs open or also capsids, are really. either are we

myself, was have for so, conversations. former Many colleagues. to And of say as them enjoying I’m these

Jack Allen

the jump I Great. for will back the in so much questions. queue. Thanks

Operator

Thank question. you. moment One for next our

from Please Our next Cowen. comes Phil ahead. go with question Nadeau

Philip Nadeau

A what morning. able measures are follow-up Can the in measures the that decision? will a for to it taking - non-human the Good more you primates on or bit between Is and talk areas about of selection our biomarkers lead brain GBAX safety a candidates? inform capture Thanks candidate transcription your select questions. in and other therapies. SODX are to there with you certain of simply the and

Alfred Sandrock

that? want you do Todd, to take

Todd Carter

Sure.

your of a So at number is question looking yes, answer are to the things. we

of the So level distribution, where the therapy the gene therapy, vector. we of look at in at off We vector when go. does go expression with look that we

So the GBA, the looking key the the where - case only the of we protein, in case are activity, activity. of vector enzymatic goes, level not

achieved the the we of knockdown case of frame SODX, ALS the relevant regions. in In program, amount

where to at go. hope we We look not also

issues that get off-target Al capsids. when will the So they earlier mentioned

look So at when those you components. all of

as hoping space, the that the delivery something it can marker how compartment the addition for we and cerebral a forward to as something we well. in transduction much that the In in a we that use And to like clinic spinal are as GBA, delivery is this as fluid for or such fluid look correlate move get for we brain. into

Philip Nadeau

your what how the these happens? probably have. appreciate I experience, How just it you model NHP? uncertainty best see follow-up. one predictive in much we measures And of remains the that NHP is model In after is

Todd Carter

are for novel capsids, our capsids. So They novel

do We increased actually experiment, in which for sure. a for family, human. gives until know the have us we think we one capsids identified translatability But human won’t we the receptor

to in the which for the won’t correlation like I think that get But know we the between a - delivery the brain we something of GBA human get sure until be of we and should translatable our delivery CSF case experiment. think humans. to will delivery,

Alfred Sandrock

Yes. proof-of-biology do I we know agree with that. for sure We human until won’t trials. the

I readouts we whether about are rely think Phil, the question, the biomarker getting In NHB the your on not or from was can studies. of, we terms that

part for be And using fooler volume larger mean just don’t I - things, large match use distances, I to of except well. think we need can a in these rodents we because animals kinds can up very the

because brain there real primates, of the for approximate mice, the than to larger is similar nothing human experiment to better CSF space, like example, are non-human Todd absolutely to be But but relatively size, as a dimensions their volumes get said. sure, human

Philip Nadeau

helpful. Thanks very is questions. That taking for that

Operator

our question. next for moment One you. Thank

Our with go ahead. Zhu Wells comes Yanan next from Please question Fargo.

Unidentified Analyst

identifying I on questions, This (Ph) the for thanks question. one on have [Quenn] Hello, for Yanan. taking is receptor, our capsids. two you one

expression receptor know the the capsids. And the So express you share you of the the what on receptor, and how factors among identify consistently you individuals affect do first levels receptor? may second on can like

So for do option, you are available further just capsids they the your them the capsids in already Thank partner your you. that exercise or use optimize the after library?

Alfred Sandrock

on to answer ask I receptor, question answer capsids. about and So ask will to the Todd I’m then that, Pete the to going the later

Todd Carter

and of know for we is the in it rodents seeing human species. seeing BBB we models what expressed in penetration and expression the receptor is in are those We delivery, animal beings. terms are primates The animal responsible the

it amongst CNS species animal that do expressed as in endothelial We don’t in different as expressed it cells in the and humans. yet have the is well. is on humans, model the readouts We and of variability know

human penetration So we the BBB and on to it those and as the improve are models ability to focused receptor well. our aspects transduce of in

Alfred Sandrock

think, know a that is the a and variability that to think second question maybe question, we order Yes. I there, a a but are And I get I mean, which add, mean, answer I within question asking is to really relates don’t could order you just which I will species. interesting second individual we yet.

to two with the to a to to relates capsid, second have years that, is it, capsid. respect then it actual I they they And was agreement the up going And understanding I out to to about Pete another talk question to after between companies. the ask think my choose because switch

So iterate, purposes. to we one, choose them as we third the - share more that more generation data of with of course may and they more capsids, second and develop newer sort which and their have option they will fit a

is how to that structured Pete. the deal my knowledge. So was

Peter Pfreundschuh

way Al, well it I think were that you themselves. have captured deals quite structured with regards to the actually

Unidentified Analyst

so you Thank it. Got much.

Operator

Thank you. moment question. One next our for

question Our next Chico ahead. Wedbush. with from comes Laura go Please

Laura Chico

Hey, taking the questions. morning Thanks guys. for good

actually gene recently release one, First guidance. CNS therapy you final

thinking out Just guidance draft campaigns? for curious you impact if relative any about development the to how anything was prior stood that there are you to to

or cash milestones of there very potential is the runway? you mentioned of that what the kind pull But some you the runway there milestone possibility second, sort to then that you runway much. provide besides extent upper I’m in can wondering does Thanks levers bound And cash and around the of payments. other

Alfred Sandrock

Pete question the about Thanks, going Todd, ask the any new to and runway. thoughts the Laura. But cash before I’m guidance. to on that,

Todd Carter

and I we concerned the general the So seen that the terms Very is consistent the what and couple, making FDA. the and think about theme seeing interested window. we about the several past in over in from particularly sure are what with in safety, have field of past therapeutic years

field. made that encouraged think are been insight the in the that by also I very from there is that the progress FDA the has they

the And therapies. ways for forward so clinic of path have the to outline into identifying gene moving they helped of

FDA we the collaborative forward. by in and so these programs of moving spirit the of the guidance very kinds excited are And

Peter Pfreundschuh

Yes.

with your regards second with runway. question, cash Laura, regards to So

regards I Al position are basically characterized We the in with company to is sheet our think balance where believe well opening remarks. we at. quite his well-capitalized

our of As of were that operating as $XXX of we quarter kind in close not sheet of in million third were noted the on included X/XX. our monies results Pfizer balance

that option in you comes extend next Novartis come the potential additional to. alluding were monies specifically could runway March with associated could as cash Pfizer which downstream, addition with agreement, milestones year, potential We those to Neurocrine you in but and due to that of associated potentially believe other reimbursements the

the every have As option. they three Street, option, described and the option programs. one a we of separate for do to would trigger on programs million Novartis of $XX.X have Each actually an capsids those each come with

we So be that could any guiding believe struck, not $XX.X although to are that a total We of time. could at those million. those be this of potentially

options And million capsid option in the addition well. $XX.X has on that to additional as take Voyager also two to

be each options, is for a could for million. million those additional that those total an So so of $XX $XX of

this that could potentially Again, time, extend to regards we We is those cash runway are with organization. all the at of going to not guiding the believe things where go.

As we got believe fair a guided cash runway take us that in still to the XXXX. quarter, into we we have

cash runway a And do as do we to today, Al, to with the of as things analysts want regards to an ongoing up are development on are having believe add all the new today conversations that we those highlight alluded opportunities, well the I that did as put earlier for business ATM. shelf potentially well. to some call also on I all could

ATM were December Our Xnd of year. actually existing shelf in expiring this

always well is shelve current We and sure in feel prudent like good an ATM. that make as place you it as to a have

things of the we think and again, help these days. operating from biopsy future is business as think those all finance And normal of could companies the organization. I that us procedure for about

Laura Chico

relative directionally thinking up about That of how Pete. one early kind ramping stages, R&D we if and expense more could helpful, still XXXX Maybe sneak I is efforts. XXXX some in be to but should super just then

So any clarity there? Thanks.

Peter Pfreundschuh

good a is question. that Yes,

this somewhere for time probably that first of million our for operating basically operating most this burn we from are year call results can $XX trajectory and million, a you between think it to kind $XX the basically on year see close XXXX. fiscal I

as forward I that, very burn. towards our burn. think operating But we the we to think cash be XXXX think street one I thing runway are of with our mindful to definitive don’t could to guidance I XXXX, we going the is regards provide do say and

regards I we be prudent going our to think investment. with capital very are to

following start again kind but now, suit least next think about XXXX, specific think we to at for of guidance with year, So there. can I XXXX no

Laura Chico

it. much Thank very you guys. Got

Operator

moment Thank our question. for next you. One

comes with Please BTIG. Yung Zhong question next ahead. from go Our

Yung Zhong

for Thank great. Okay, you very much question. the taking

our sorry, - so DRG The And sorry. IV TRACER and de-targeting question toxicity liver platform, if please. is And capsid, to IV how is DRG built you are sticking de-targeting the for approach? important into one

Alfred Sandrock

This is Al.

it think I is very important.

precedence delivered produce to there think IV capsids I is toxicity. for DRG

We And is see the de-targeting and do door. the have the into we so so think capsids of some capsids these they attribute of important while it increased with we CNS. of far identified tropism that that, delivery

are transduction exactly we we want in the I that want less point getting toxicity So to expression the be cells we would would than And cells transduce DRG that not. rather would in what we out that seem increased to this related. does

it And some have that we ganglion great de so root that target dorsal I neurons. think is capsids

Yung Zhong

Okay.

in the started capsids and variant maybe the you crossing the antibody anybody, is please? level fromAAVX and believe terms platform, the you also Thank wall that given pre-existing of another and consistent So pre-existing advantage neutralizing blood-brain-barrier. across question neutralizing you. in the identify of potency is TRACER type the AAVX normally is But reason through I main you the

Alfred Sandrock

is great Yes. a question. No that

our of added you we starting platform. neurotropic and did AAVX the both And actually king the why the as right, capsids is AAVX of sort AAVX, we So TRACER are capsids. AAVX the for use reason

the to best wanted that on patients we is pre-existing AAVX has improve attribute there the have. that we one many that have fewer So very antibodies.

test capsids, we can question of can increases your immunogenicity quite So actually we the using patients can numbers too. of substantially that - capsids. And we about by treat novel the AAVX actually

we parent to relative less access pre-existing - and whether more have test that can their capsids. We capsids have the novel to antibodies patients immunogenicity are our and or

Todd, to add you anything? want

Todd Carter

add alterations with the Al. case. AAVX Everything that there AVV the activity AVVX Thanks with Yes. capsids, be specific in We are we to to the making will in changes those neutralization population that said, Al I particular this families. don’t the, in and expect

though pre-existing identifying for be prospect, could the identify activity. by with our platform that also excited less capsids. are these We to deployed TRACER capsids be neutralization novel Can

we in future And forward work the platform. with looking so that moving forward are and capsids our to are

Yung Zhong

Great. Thank you very much.

Operator

next our question. Thank you. One moment for

Our next Please with Leone Raymond ahead. go question comes Dane James. from

Dane Leone

Hi thanks taking my all the and on congrats for progress. questions

it work aspect patients protein for the of SMNX I similar were think was and somewhat a different might I on able of where Vector had by you vein questions, protein two So interesting DNA be and will the passed but of gene - helpful. kind way, There ask a the which in an organs. that expression different away evaluated also of unfortunately to they SMN the be

the I When these and of really I optimizing there to are is here. couple biodistribution the do an predict in mean, capsids you what think dial angles ability there is where to the are you the you guess and a across trying the happened. is trophism. pretty major which management localizing? liver Obviously on there also was toxicity was organs. much created DNA a case there of in But vector DNA all of lot the the some that gene SMNX a vector in

was protein neurons. really spinal SMN around localized, the expression the more motor Although in

and there I sector train like actual out actually vector? like much So expression the is can guess the some kind two toxicity things potentially you DNA here, the hanging where how versus of is of in protein dial

Alfred Sandrock

to safety. Yes. we about a No, central of of lot are terms what that in thinking is

why look RNA we point protein, as DNA. get is when the our to actually have. so we the thing are great DNA, those to mRNA look that help and And about well the de-targeting cells. in DNA And we both choosing of that delivery at can data we And as capsids various by it we excited us And of can at messenger that with capsid. cells

at three. So all we can look

related the some few of and protein toxicity a is paper by out from expression some Columbia expression may out, pointed as years be pointed related, the ago. SMN you as And

Some related. may not expression be

versus can Some ways that may perhaps toxic. be other the simply and capsid be immunogenicity gene therapy

consider potential So all which avenues, can these be we to by toxicity displayed. have

think that novel level And fine really very selection, with helpful. is we that can promoter be expression derived tune is from capsids we a if potentially that unprecedented. target to certainly having I TRACER organs combine can

And so, do add Todd, anything you have to to that?

Todd Carter

I mRNA aspects of is from the TRACER think the one based key platform. the readout

with are so at we is delivery. not that And we TRACER us successful making looking what the just is expression delivery, DNA mRNA level platform to DNA really the hone in on addition in

you look we multiple some profiles for capsid So tissue imagine when tissues, our different at probably the caps evaluate more, indications. all would we build and and our

really and therapeutic that so And capsid fits profile need. and the we window build the to we try give that identify us do to profile

component we don’t a we it are when in is a get type One particular other there less think of and ways where about The more we is, tissue want we different targeting where want and we couple get literally others. de-targeting it. cell in or

other is, which getting in potency of the context then off delivery can target improve to tissue, dose, the the our also and target The tissues. lower to we the itself if reduces we can

our have those we opportunities of TRACER platform. so both in And

Dane Leone

you. Thank

Operator

Thank question. you. One our for moment next

Our Please with Kulkarni from go Canaccord next Sumant question comes ahead. Genuity.

Sumant Kulkarni

question. for Thanks morning. taking Good my

there specific any to surface cell binding one known the that CNS downsides to already that some But specific a are specific receptor? identified. novel to you have on be advantages to Clearly, appear there bio-distribution. Just capsid related chip

Alfred Sandrock

of the not second sentence. Can understood you - sure second I’m question? I repeat your quite Not part the

Sumant Kulkarni

kind be are this to I manage that downsides mean, and response might of to anything there any how Are you already the known utilizing toxicity receptor able that you or that? that around get need. like

Alfred Sandrock

was, receptor that around? this question the manage would question? the think I Is known anything there to So need about we even potentially is that

Sumant Kulkarni

exactly. Yes,

Alfred Sandrock

Yes.

So that of right to would need anything now, around. we manage we don’t know

that. leave just will it I So at

Sumant Kulkarni

Got it. Thank you.

Operator

moment One you. question. next for Thank our

Please with ahead. question next from comes Our Jack go Baird. Allen

Jack Allen

I that may and proof-of-concept potentially? so comment have. partners, to potential clinic thoughts you for to the well, it data is to the those I follow-up. Is of hear your by at relates Thank as the but it moving any it getting candidates for would are progress hard know programs in programs love you Pfizer’s related much timing taking as Novartis opted the to any to

Alfred Sandrock

Yes, Jack.

could get But lead So and will more I the relatively for about they our programs. specificity plans. can to I’m around we I be they us, is about right are specific the They going our be timelines. are tell all these tell time theirs. sure wish But let to the have you. when specific when own of And partners we

Jack Allen

about your Okay. guess one to has space. amyloid with close some think I beta brief really there that tau I have follow-up. plans hear on you just been know the going Al, to is the Alzheimer’s And then beta expected. yourself? Pete the impact be generally here for development around does antibody is corner data and I the interesting amyloid have any

Alfred Sandrock

question. a is good It

So it I Biogen for treatments. and that, press disease think sound like very release does read the does Alzheimer’s only from - have do exciting it I times and

dawn think the I patients because personally, think I currently which something disease, than - Alzheimer’s think very certainly more available therapy. treatments the I of on we for is welcome are need new

impacts it program. how is our that anti-tau So

past. What I disease the has from R&D, previous from that failures would Alzheimer’s there the and notice been field field of has in is we learnings the studies successes in benefited use that, both always that and

to looking I’m it program. And that data I’m be bringing we at learnings sure our will to in And incorporate so, that from few a the weeks. forward there will CTAD

Jack Allen

follow the for much Okay. Thanks taking so ups.

Operator

time. like further at no it showing back Sandrock would this I’m closing to you. remarks. now Thank turn questions I to for Dr. Al

Alfred Sandrock

on questions. everyone interesting thank and very to important joining for and us wanted say Well, I for us you call. just you the some asking Appreciate being

Operator

in Thank conference. This program. concludes today’s you participation the for your

You may now disconnect.

Voyager Therapeutics (VYGR) 8 Nov 222022 Q3 Earnings call transcript